Using MIPs for medicine
– Imprinting a difference
Welcome to MipSalus
MipSalus is dedicated to developing new, non-systemic pharmaceutical drugs for treatment of metabolic orphan diseases
ABOUT THE COMPANY
MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. MipSalus currently focuses on developing a breakthrough treatment for the rare and potentially invalidating disease Phenylketonuria (PKU) using phenylalanine-binding MIPs to prevent uptake of surplus dietary phenylalanine (Phe) in the body.
The name MipSalus is a combination of the abbreviation MIP – Molecular Imprinted Polymers – and Salus, the ancient Roman goddess of health and prosperity.
Furthermore, building on the PKU drug development project and using company’s Phe-binding MIPs, MipSalus has obtained in-vitro proof of concept for a home sensor that will enable PKU patients to monitor their disease and swiftly adjust food and medication accordingly.